LIC IPO may recreate the Maruti moment of 2003 for markets: Nilesh Shah

Every dip will be a buying opportunity and capital Goods, real estate, infrastructure and pharma may outperform going forward, believes Nilesh Shah.
Read moreEvery dip will be a buying opportunity and capital Goods, real estate, infrastructure and pharma may outperform going forward, believes Nilesh Shah.
Read moreNippon India Pharma Fund appears well-positioned to take advantage of the under penetration of pharmaceuticals and healthcare services in India and other emerging markets. The fund’s penchant for companies catering to specialty businesses in the developed markets might prove handsomely rewarding in the long run.
Read moreBeing on the right side of manufacturing compliance is the key for Indian pharma companies. A complex product portfolio and cost effectiveness would matter too. But potential drug discoveries may have a joker-in-the-pack effect.
Read moreTorrent Pharma has recently begun to plot an upmove on the back of continuous buying. We take you through the chart, indicating long and short term stop-losses and potential appreciation.
Read moreThere has been little respite lately for India’s stumbling economy, lashed by close to double-digit inflation and a rupee that fell by 16% in the past year. That wiped out any gain from the 12% rise of the stock market, resulting in a lackluster 3% growth in the wealth of India’s 100 richest, to $259 billion. There has been little
Read more